Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) have earned an average rating of "Moderate Buy" from the seven analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $16.57.

A number of equities analysts recently commented on OCUL shares. Robert W. Baird dropped their price target on Ocular Therapeutix from $18.00 to $17.00 and set an "outperform" rating for the company in a research note on Thursday, August 8th. HC Wainwright reaffirmed a "buy" rating and set a $14.00 price objective on shares of Ocular Therapeutix in a report on Wednesday, October 16th. Finally, Scotiabank started coverage on shares of Ocular Therapeutix in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $22.00 target price for the company.

Ocular Therapeutix Stock Down 1.3 %

NASDAQ OCUL opened at $10.39 on Friday. Ocular Therapeutix has a 12 month low of $2.00 and a 12 month high of $11.77. The company has a current ratio of 16.64, a quick ratio of 16.55 and a debt-to-equity ratio of 0.18. The stock has a market cap of $1.62 billion, a PE ratio of -7.70 and a beta of 1.29. The stock's 50 day moving average is $9.49 and its 200 day moving average is $7.63.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.04). The company had revenue of $16.40 million for the quarter, compared to the consensus estimate of $15.85 million. Ocular Therapeutix had a negative return on equity of 52.75% and a negative net margin of 226.46%. Ocular Therapeutix's revenue was up 7.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.27) EPS. Research analysts predict that Ocular Therapeutix will post -1.02 EPS for the current fiscal year.

Institutional Trading of Ocular Therapeutix

Several hedge funds and other institutional investors have recently bought and sold shares of OCUL. Avoro Capital Advisors LLC boosted its stake in Ocular Therapeutix by 12.7% during the second quarter. Avoro Capital Advisors LLC now owns 8,060,000 shares of the biopharmaceutical company's stock worth $55,130,000 after buying an additional 911,064 shares during the period. Vanguard Group Inc. grew its holdings in Ocular Therapeutix by 41.4% during the 1st quarter. Vanguard Group Inc. now owns 7,235,131 shares of the biopharmaceutical company's stock valued at $65,840,000 after purchasing an additional 2,117,029 shares during the last quarter. Opaleye Management Inc. raised its position in Ocular Therapeutix by 9.6% in the 1st quarter. Opaleye Management Inc. now owns 6,653,138 shares of the biopharmaceutical company's stock worth $60,544,000 after purchasing an additional 583,138 shares during the period. Assenagon Asset Management S.A. purchased a new stake in shares of Ocular Therapeutix in the third quarter worth approximately $24,584,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Ocular Therapeutix during the second quarter worth $18,514,000. Hedge funds and other institutional investors own 59.21% of the company's stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.